You appear to be focused on the least important part of the business at the moment, revenue.
This is a biotechnology company conducting clinical trials. Anyone invested knows it needs to spend capital on R&D to develop IP which is how the market cap and price will be rerated.
Remember the company just released Phase 2 in-human trial results for OSA that effectively cured the condition for patients. If that program continues to deliver results in the pivotal study then it’s potentially worth multiple billions.
Bob Clark didn’t set his milestones around revenue because as a big Pharma executive he knows that it’s the drug IP that will generate a potential takeover. And his first option hurdle is $1.00 a share.
IHL Price at posting:
25.8¢ Sentiment: Buy Disclosure: Held
